

## Drug Monograph

Drug/Drug **Inflectra<sup>®</sup> (infliximab-dyyb) injection/ Immunomodulators**

Class:

Prepared for: MO HealthNet

Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Inflectra <sup>®</sup> is available in a 20 ml vial containing 100 mg lyophilized infliximab-dyyb.
<b>Manufacturer:</b>	Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512
<b>Indications:</b>	Inflectra <sup>®</sup> is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in the following disease states: Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis in combination with methotrexate, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.
<b>Costs:</b>	\$955.74 per 100 mg vial of Inflectra <sup>®</sup> . Wholesale Acquisition Cost
<b>Summary of Findings:</b>	This drug is being considered for inclusion in the state specific Preferred Drug List.
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> Non Preferred

Prepared By: Luke Boehmer Pharm.D.

Date: February 16, 2017